The Post-Transplant Lymphoproliferative Disorder drugs in development market research report provides comprehensive information on the therapeutics under development for Post-Transplant Lymphoproliferative Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Post-Transplant Lymphoproliferative Disorder. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Post-Transplant Lymphoproliferative Disorder and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Post-Transplant Lymphoproliferative Disorder by 11 companies/universities/institutes. The top development phase for Post-Transplant Lymphoproliferative Disorder is preclinical with six drugs in that stage. The Post-Transplant Lymphoproliferative Disorder pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Post-Transplant Lymphoproliferative Disorder pipeline products market are: Viracta Therapeutics, bluebird bio and Atara Biotherapeutics.
The key targets in the Post-Transplant Lymphoproliferative Disorder pipeline products market include Transferrin Receptor Protein 1 (T9 or p90 or CD71 or TFRC), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19).
The key mechanisms of action in the Post-Transplant Lymphoproliferative Disorder pipeline product include Histone Deacetylase (HDAC or EC 3.5.1.98) Inhibitor with one drug in Phase II. The Post-Transplant Lymphoproliferative Disorder pipeline products include nine routes of administration with the top ROA being Intravenous and seven key molecule types in the Post-Transplant Lymphoproliferative Disorder pipeline products market including Monoclonal Antibody, and Gene-Modified Cell Therapy.
Post-Transplant Lymphoproliferative Disorder overview
Post-Transplant Lymphoproliferative Disorder is a complication of organ transplantation and is a life-threatening condition. Infections occurring because of low immunity like EBV (Epstein-Barr virus) also known common cause. Symptoms are non-specific and varies from one another but most commonly fever, malaise, weight loss are seen. EBV tests, CBP, Urine analysis, CT-scan, PET scan are the common diagnostics methods. As Immunosuppressants are one cause of PTLD, treatment approach is to reduce the immunosuppression and restore cellular immunity. Monoclonal antibodies rituximab is the standard of care in PTLD patients. Chemotherapy and radiation therapy are also chosen.
For a complete picture of Post-Transplant Lymphoproliferative Disorder’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
